AbbVie said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections ...

Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...

AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...

Maybe you've been in a room recently with someone who's coughing, but they say "I promise it's not COVID." While it's important to still be cautious about COVID-19, there are other viral ...

If the FDA follows an advisory committee’s vote, it can potentially be a transformative step in the delivery of mental health ...

Here are the top 7 diseases that can lead to the leakage of blood via your urine. This one signs could indicate kidney ...

Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.

What is helping drive the increase of drug-resistant infections in Ukraine, why should the UK be on alert, and importantly, what can be done about it?

A groundbreaking cannabinoid-based antimicrobial, Silvanex, fights drug-resistant infections with a synergy of silver, CBC ...

AbbVie receives US FDA approval for Emblaveo to treat adults with complicated intra-abdominal infections with limited or no treatment options: North Chicago, Illinois Monday, Febr ...

The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options.

A team from Osaka University has developed scSPOT, a new technique that reveals how immune cells called Tregs simultaneously ...